Simplifying Downstream Processing for Complex Biologics

Downstream processing can be the cause of a bottleneck in manufacturing, particularly for complex biologics, leading to a need for simpler platform approaches, according to Kenneth Holbourn from FUJIFILM Biotechnologies. As the bio/pharma industry increasingly diversifies into niche and complex modalities, the limitations of purification approaches currently used in downstream processing are becoming more apparent. Rather than continuing to use the one-off strategies, companies are demanding standardized, platform options to improve efficiencies. To answer these demands, FUJIFILM Biotechnologies recently unveiled ShunzymeX — a precision purification technology that has been designed to harmonize the downstream workflow. In this technical interview, Kenneth Holbourn discusses how ShunzymeX is relieving the downstream burden and allowing for flexibility.